OncoMatch

OncoMatch/Clinical Trials/NCT05766748

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Is NCT05766748 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Azeliragon for metastatic pancreatic cancer.

Phase 1/2RecruitingCantex PharmaceuticalsNCT05766748Data as of May 2026

Treatment: Azeliragon — This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Disease stage

Metastatic disease required

locally advanced or metastatic adenocarcinoma of the pancreas for which potential curative measures, such as resection of an isolated metastasis, are not available

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: Gemcitabine/Abraxane or FOLFIRINOX-based regimen (gemcitabine, nab-paclitaxel, FOLFIRINOX)

previously been treated with a Gemcitabine/Abraxane or FOLFIRINOX- based regimen

Lab requirements

Blood counts

ANC ≥ 1.0 × 10^9/L; Platelet count ≥ 75,000/mm3 (75 × 10^9/L); Hemoglobin (Hgb) ≥ 9 g/dL without transfusion or growth factor support

Kidney function

Estimated creatinine clearance of > 60 mL/min (per Cockroft-Gault formula)

Liver function

AST (SGOT), ALT (SGPT) ≤ 2.5 × ULN, unless liver metastases are present, then ≤ 5 x ULN is acceptable. Total bilirubin ≤ 1.5 × ULN.

adequate biological parameters as demonstrated by the following blood counts...AST (SGOT), ALT (SGPT) ≤ 2.5 × ULN, unless liver metastases are present, then ≤ 5 x ULN is acceptable. Total bilirubin ≤ 1.5 × ULN. Estimated creatinine clearance of > 60 mL/min (per Cockroft-Gault formula)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute · Los Angeles, California
  • Boca Raton Regional Hospital, Lynn Cancer Institute · Boca Raton, Florida
  • Williamette Valley Cancer Institute and Research Center · Eugene, Oregon
  • AHN Cancer Institute - Allegheny General Hospital · Pittsburgh, Pennsylvania
  • Prisma Health - Upstate · Greenville, South Carolina

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify